A Randomized, Open-label, Single Dose, Crossover, Phase 1 Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-383 in Healthy Volunteers
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Lobeglitazone/D745/D150-Chong-Kun-Dang (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Chong Kun Dang
Most Recent Events
- 17 Jul 2024 New trial record